FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote

TUESDAY, Sept. 6, 2022 -- A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for amyotrophic lateral sclerosis (ALS), a rare second review for a disease that has no cure. The same panel that will...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news